Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis.
Alcoholic liver disease
Alcoholic liver disease (ALD)
Biomarkers
E-selectin
Hepatic inflammation; patient outcomes
ICAM-1
Vascular cell adhesion molecule 1 (VCAM-1)
Vascular dysfunction
Von-Willebrand Factor
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
04
12
2020
accepted:
22
02
2021
pubmed:
7
5
2021
medline:
25
2
2023
entrez:
6
5
2021
Statut:
ppublish
Résumé
Alcoholic hepatitis (AH) is a severe condition characterized by a marked inflammatory response and high short-term mortality. Endothelial dysfunction (ED) is an early event in vascular and inflammatory disorders. The aim of this study is to evaluate ED in AH patients. Prognostic value of ED biomarkers was evaluated in patients with severe AH (n = 67), compensated alcoholic cirrhosis (n = 15), heavy drinkers without liver disease (n = 15) and controls (n = 9), and in a validation cohort of 50 patients with AH. Gene expression of ED markers was analyzed in liver tissue. Plasma levels of ED markers such as vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin and von Willebrand factor (vWF) increased along alcohol-related liver disease (ALD) progression. Intergroup analysis showed a significant increase of these markers in AH patients. In addition, VCAM-1 showed a positive correlation with Maddrey, MELD and ABIC scores and inflammation parameters (i.e. C-reactive protein and LPS levels). Importantly, levels of VCAM-1 were higher in patients with increased mortality and were independently associated with short-term survival (90-day) when adjusted by ABIC score. These results were confirmed in an independent cohort of AH patients. In addition, severe AH patients showed altered hepatic expression of ED markers. In this study we show that advanced ALD and particularly severe AH is associated with an increase of ED biomarkers, which correlate with patient outcomes. These results suggest that ED may be a pathogenic event in AH and highlight endothelial factors as potential biomarkers in AH.
Identifiants
pubmed: 33954832
doi: 10.1007/s12072-021-10165-y
pii: 10.1007/s12072-021-10165-y
pmc: PMC10113804
mid: NIHMS1880703
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006-1017Subventions
Organisme : NIAAA NIH HHS
ID : 1U01AA021908
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026972
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA021908
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NIAAA NIH HHS
ID : 1U01AA021908-01-33490
Pays : United States
Informations de copyright
© 2021. Asian Pacific Association for the Study of the Liver.
Références
N Engl J Med. 2015 Apr 23;372(17):1619-28
pubmed: 25901427
Int J Obes (Lond). 2017 Aug;41(8):1207-1213
pubmed: 28461687
Circulation. 2001 Jan 30;103(4):491-5
pubmed: 11157711
Alcohol Clin Exp Res. 1998 Sep;22(6):1324-7
pubmed: 9756049
Gene Expr. 2017 Nov 27;17(4):301-312
pubmed: 28770701
Am J Gastroenterol. 2020 Mar;115(3):398-405
pubmed: 31985531
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2046-2054
pubmed: 31811953
BMC Genomics. 2018 Mar 9;19(1):188
pubmed: 29523084
Hepatology. 2016 Oct;64(4):1343-55
pubmed: 26940353
Gut. 2011 Aug;60(8):1133-8
pubmed: 21427197
Obes Res. 2003 Nov;11(11):1278-89
pubmed: 14627747
J Hepatol. 2014 Oct;61(4):912-24
pubmed: 24911462
Int J Biol Sci. 2013 Nov 09;9(10):1057-69
pubmed: 24250251
J Hepatol. 2019 Feb;70(2):273-283
pubmed: 30658728
Am J Gastroenterol. 2020 Nov;115(11):1857-1868
pubmed: 33156105
Hepatology. 2009 Aug;50(2):638-44
pubmed: 19575462
Hepatology. 2015 Sep;62(3):762-72
pubmed: 25761863
World J Gastroenterol. 2014 Mar 14;20(10):2555-63
pubmed: 24627591
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):231-42
pubmed: 25782093
Hepatology. 2017 Aug;66(2):555-563
pubmed: 28120471
Lancet. 1981 Mar 28;1(8222):707-11
pubmed: 6110925
Alcohol Clin Exp Res. 2001 Feb;25(2):261-8
pubmed: 11236841
Liver Int. 2019 Jul;39(7):1246-1255
pubmed: 30597709
Hepatol Int. 2017 May;11(3):255-267
pubmed: 28247264
Alcohol Clin Exp Res. 2005 Dec;29(12 Suppl):264S-71S
pubmed: 16385234
Nat Rev Dis Primers. 2018 Aug 16;4(1):16
pubmed: 30115921
J Hepatol. 2014 Dec;61(6):1321-7
pubmed: 25038487
Sci Rep. 2016 Aug 31;6:32341
pubmed: 27578545
Alcohol Clin Exp Res. 2020 May;44(5):1075-1087
pubmed: 32246771